Addex Therapeutics (ADXN) Operating Income (2018 - 2026)
Addex Therapeutics (ADXN) posted Operating Income of -$612741.3 for Q1 2026, up 37.15% sequentially from -$974990.3 in Q4 2025, and up 9.13% YoY from -$561471.5 in Q1 2025.
Addex Therapeutics (ADXN) Operating Income (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Operating Income for 9 years, with the latest figure at -$612741.3 in Q1 2026.
- Quarterly Operating Income rose 9.13% year-over-year to -$612741.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 million (up 39.56% YoY) and the FY2025 annual result came in at -$3.4 million, down 8.39% from the prior year.
- Operating Income advanced to -$612741.3 in Q1 2026 per ADXN's latest filing, from -$974990.3 in the prior quarter.
- Over five years, Operating Income peaked at -$397495.9 in Q1 2023 and troughed at -$21.3 million in Q4 2022.
- A 5-year average of -$3.1 million and a median of -$902903.1 in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income soared 94.02% in 2023, then sank 127.15% in 2024.
- Over 5 years, Operating Income stood at -$21.3 million in 2022, then jumped by 88.13% to -$2.5 million in 2023, then dropped by 24.37% to -$3.1 million in 2024, then surged by 69.0% to -$974990.3 in 2025, then soared by 37.15% to -$612741.3 in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$612741.3, -$974990.3, and -$870295.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -612,741.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -612,741.33 |
| Dec 31, 2025 | -974,990.33 |
| Sep 30, 2025 | -870,294.99 |
| Jun 30, 2025 | -885,260.33 |
| Mar 31, 2025 | -674,315.23 |
| Dec 31, 2024 | -3.14 Mn |
| Sep 30, 2024 | -718,146.59 |
| Jun 30, 2024 | -994,457.78 |
| Mar 31, 2024 | -902,903.07 |
| Dec 31, 2023 | -2.53 Mn |
| Sep 30, 2023 | -848,251.72 |
| Jun 30, 2023 | -440,623.93 |
| Mar 31, 2023 | -397,495.91 |
| Dec 31, 2022 | -21.30 Mn |
| Sep 30, 2022 | -4.31 Mn |
| Jun 30, 2022 | -7.36 Mn |
| Mar 31, 2022 | -6.24 Mn |
| Dec 31, 2021 | -16.82 Mn |
| Sep 30, 2021 | -3.89 Mn |
| Jun 30, 2021 | -4.94 Mn |